BRØNDBYERNES I.F. FODBOLD A/SCVR-nr. 83 93 34 10 Brøndby, den 26. september 2025 SELSKABSMEDDELELSE NR. 9/2025 Indkaldelse til ordinær generalforsamling i Brøndbyernes I.F. Fodbold A/S Der indkaldes hermed til ordinær generalforsamling i Brøndbyernes I.F. Fodbold A/S, CVR-nr. 83 93 34 10 (”Selskabet”). Generalforsamlingen afholdes tirsdag den 21. oktober 2025, kl. 16:00, på adressen: Brøndby Stadion 28, Michael Laudrup Lounge, 2605 Brøndby. Dagsorden Forelæggelse af årsrapport med revisionspåtegning til god ...

Core Viewpoint - Tonner Drones has initiated a capital increase for shareholders with preferential rights to strengthen its cash position for R&D and investment, as well as to reduce debt and financial costs [2][3]. Group 1: Capital Increase Details - The capital increase is expected to raise approximately €1.05 million to €1.2 million, with a dilution limited to 7% to 8% [4]. - Shareholders can subscribe to the capital increase at a price of €0.0270 per share, with the subscription right allowing them to buy 1 additional share for every 14 shares owned [5]. - The subscription period ends on October 1, 2025, although some financial institutions may have earlier deadlines [5]. Group 2: Subscription Rights and Warrants - All shareholders will receive subscription rights that can be publicly traded from September 23 to September 29, 2025 [6]. - The company will issue warrants (BSA) to shareholders, allowing them to purchase shares in the future under favorable conditions [7][8]. - Shareholders participating in the capital increase will receive BSA-1 and possibly BSA-2, while BSA-3 will be distributed to all shareholders similarly to a previous issuance in August 2024 [8][11]. Group 3: Indicative Timetable - The indicative timetable for the capital increase includes key dates such as the opening of the subscription period on September 25, 2025, and the closure of the subscription period on October 1, 2025 [13]. - The results of the operation will be announced on October 6, 2025, followed by the issuance and trading of new shares and BSA on October 8, 2025 [13]. Group 4: Company Overview - Tonner Drones develops technologies for the logistics sector and holds stakes in promising French drone manufacturers, focusing on increasing the value of these investments through active asset management [15]. - The company aims to retain R&D for its products in France while not planning to own a factory [15].

Core Viewpoint - Tonner Drones is launching a capital increase through preferential subscription rights (PSR) to raise approximately €1 million by issuing new shares at a subscription price of €0.027 per share, accompanied by share subscription warrants [1][5][12]. Group 1: Capital Increase Details - The capital increase aims to issue a maximum of 38,841,273 new shares, potentially increasing to 44,667,463 shares if the extension clause is exercised, with gross proceeds of up to €1,206,021.50 [8][29]. - The subscription period for the new shares will be from September 25 to October 1, 2025, and the subscription ratio is set at 1 ABSA for every 14 existing shares [5][17]. - The subscription price of €0.027 per share represents a discount of 6.67% compared to the weighted average share price over the last ten trading sessions and a discount of 14.83% compared to the market price on September 11, 2025 [12][13]. Group 2: Objectives and Use of Proceeds - The capital increase is intended to reduce the company's debt, strengthen cash flow, enhance the R&D and investment budget, and further reduce costs by repaying part of the existing debt [6][3]. - The Chairman and CEO, Diede van den Ouden, has committed to guarantee 50% of the transaction and will subscribe to the new shares, demonstrating confidence in the company's future [3][43]. Group 3: Shareholder Impact - Following the capital increase, the largest shareholder, Diede van den Ouden, will increase his stake from 12.04% to 14.57%, while the audience's stake will decrease from 87.96% to 82.10% [46]. - Shareholders who do not participate in the capital increase will experience dilution of their ownership percentage [47]. Group 4: Subscription Rights and Warrants - Each new share will be accompanied by a BSA 2025-1 warrant, allowing the holder to subscribe to one new share at an exercise price of €0.029 until January 9, 2026 [2][9]. - The BSA 2025-2 will allow the holder to subscribe to two new shares at an exercise price of €0.025 from June 30, 2026, to December 29, 2028 [10][33]. Group 5: Timeline and Regulatory Aspects - The timeline for the capital increase includes key dates such as the detachment of preferential subscription rights on September 23, 2025, and the expected settlement and delivery of new shares on October 8, 2025 [40][32]. - The operation does not require a prospectus as the total amount is below €8 million, and the company will publish necessary regulatory notices [50][51].

Core Points - Bavarian Nordic A/S has increased its share capital by DKK 3,818,710 due to the exercise of employee warrants [1] - The capital increase was executed without pre-emption rights for existing shareholders, resulting in total proceeds of DKK 78.7 million [2] - The new shares will be listed on Nasdaq Copenhagen and will have the same rights as existing shares, bringing the total nominal value of share capital to DKK 792,367,280 [3] - The announcement does not alter the company's financial expectations for 2025 [4] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines [5]

Core Viewpoint - CROSSJECT successfully completed a capital increase of €5.7 million, which will support the final registration phases of ZEPIZURE®, its emergency treatment for epileptic seizures [2][3][18] Financing Details - The capital increase was achieved through a preferential subscription rights offering, with a gross amount of €5,725,479.20 and a net amount of approximately €5,458,093.69 [2][3] - The subscription price was set at €1.40, reflecting a 22.6% discount to the closing price on June 3, 2025 [3] - Total demand for the offering reached €9.2 million, resulting in an oversubscription rate of 1.84 times the initial offering [9][18] Use of Proceeds - Approximately 60% of the net proceeds will be allocated to the final development phases of ZEPIZURE® and initial production stages [6] - The remaining 40% will finance R&D for other projects, including ZENEO® Adrenaline and ZENEO® Hydrocortisone, and cover general administrative expenses [6] Development Timeline - CROSSJECT is on track for the EUA submission to the FDA and anticipates a confirmation of receipt within one month after submission [5] - The company is also preparing for a second NDA filing for ZEPIZURE® in the second quarter of 2026 [6] Shareholder Impact - Following the capital increase, the company's share capital will amount to €5,032,022.40, comprising 50,320,224 shares [11] - Gemmes Venture, a significant shareholder, subscribed €62,460, reducing its stake from 24.7% to approximately 22.0% post-transaction [12] Legal and Regulatory Framework - The capital increase was authorized by the Supervisory Board and executed in accordance with the resolutions from the Combined General Meeting [8] - The new shares will be listed on Euronext Growth and will be fully assimilated to existing shares upon issuance [26][27]

Core Points - Crédit Agricole S.A. is launching its annual capital increase reserved for employees globally [1] - The capital increase will allow 190,000 eligible employees and retired former employees to subscribe to new shares at a discounted price [2] - The subscription price will be set at the arithmetic mean of opening share prices from May 26 to June 20, 2025, with a 20% discount [2] - The subscription period is from June 24 to July 8, 2025 [2] - New shares will be issued on August 28, 2025, and will be eligible for dividends for the 2025 financial year [3] - A maximum of 32 million shares will be issued, with a par value of €96 million [3] - Following the capital increase, a share buyback operation will be conducted to mitigate dilution, pending ECB approval [3] - This initiative is part of the Group's employee profit-sharing policy related to financial performance [3]

Core Points - CROSSJECT plans to launch a capital increase of approximately 5 million euros, potentially increasing to 5.8 million euros, to support commercial and production activities related to the EUA approval of ZEPIZURE® [2][3][8] - The capital increase aims to provide financial resources for the final development phases of ZEPIZURE® and to initiate production steps, with a significant portion allocated to R&D for other projects [8][10] Offer Details - The capital increase will be executed through the issuance of new shares with preferential subscription rights, as authorized by the Supervisory Board and the Annual General Meeting [4][5] - The net proceeds will be allocated approximately 60% to ZEPIZURE® development and production, and 40% to R&D for other projects, repayment of financial creditors, and general expenses [8][9] Financial Strategy - If the Offer is limited to 75% of the issue, around 3.8 million euros, the allocation will be on a pro rata basis, prioritizing ZEPIZURE® activities [9] - The company estimates that the net working capital from the Offer will be sufficient to meet obligations until the end of 2025, assuming first payments from the US partner [10] Shareholder Support - Gemmes Venture, a 26% reference shareholder, intends to guarantee the Offer in cash up to 75% of the initial amount [11] - Heights Capital Management has indicated its intention to subscribe to the capital increase by offsetting its claim of around 0.5 million euros [12] Company Overview - CROSSJECT is a specialty pharmaceuticals company developing emergency medicines, with ZEPIZURE® in advanced regulatory development and a $60 million contract with BARDA [15][16] - The company utilizes its ZENEO® platform for easy delivery of emergency drugs via intramuscular injection [15]

Core Points - VINCI is conducting a capital increase reserved for its employees in France as part of its savings plan, with the authority delegated by the shareholders' meeting on April 9, 2024 [1][2] - The subscription period for employees to participate in the capital increase will run from May 1 to August 31, 2025 [3] - The issue price for the new shares is set at €97.21, which is 95% of the average opening prices of VINCI shares over the 20 trading days preceding February 6, 2025 [4] - The total number of new shares issued will not exceed 1.5% of the authorized share capital as determined by the shareholders' meeting [5] - The "Castor Relais 2025/2" mutual fund will subscribe to the new shares, which will be admitted to trading on Euronext Paris after their creation [6]